Sino-America Chinmedomics Technology Collaboration Center, National TCM Key Laboratory of Serum Pharmacochemistry, Chinmedomics Research Center of State Administration of TCM, Metabolomics Laboratory, Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin 150040, China.
Sino-America Chinmedomics Technology Collaboration Center, National TCM Key Laboratory of Serum Pharmacochemistry, Chinmedomics Research Center of State Administration of TCM, Metabolomics Laboratory, Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin 150040, China.
Phytomedicine. 2019 Feb 15;54:328-338. doi: 10.1016/j.phymed.2018.04.015. Epub 2018 Apr 10.
Yinchenhao decoction (YCHD) has been widely applied in the clinic for various kinds of liver disease, especially for the therapy of dampness-heat jaundice syndrome (DHJS). Some studies have investigated the pharmacological activity and compositions of YCHD. However, its Q-markers and the action targets are still unrevealed.
This work aims to clarify the therapeutic effect of YCHD against DHJS and discover the quality-markers (Q-markers) of YCHD based on the high-throughput chinmedomics strategy and then predict the potential targets and action mechanism of YCHD against DHJS.
Ultra-high performance liquid chromatography/mass spectrometry (UPLC-MS) combined with pattern recognition method was utilized to analyze serum samples and urine samples. Multivariate data analysis and network pharmacology technology were used to identify the effective components and biomarkers associated with therapeutic effects.
With the high sensitivity UPLC-MS technology, a total of 69 compounds from YCHD were identified and 41 of them were absorbed in blood. Besides, 34 urine biomarkers from DHJS were identified. Of note, we utilized chinmedomics technology on the correlation analysis of urine biomarkers and absorbed components to determine 9 core-compounds as the Q-markers responsible for the efficacy of YCHD. Finally, a total of 12 potential targets were discovered.
This work provides a powerful method for clarifying the efficacy of TCM and discovering the effective ingredients as Q-markers.
茵陈蒿汤（YCHD）已广泛应用于各种肝病的临床治疗，尤其在湿热黄疸综合征（DHJS）的治疗中。已有研究对 YCHD 的药理活性和成分进行了研究。然而，其质量标志物（Q-markers）和作用靶点仍未被揭示。
本研究旨在基于高通量中药组学策略阐明 YCHD 治疗 DHJS 的疗效，并发现 YCHD 的质量标志物（Q-markers），进而预测 YCHD 治疗 DHJS 的潜在靶点和作用机制。
采用超高效液相色谱/质谱联用（UPLC-MS）结合模式识别方法分析血清和尿液样本。采用多元数据分析和网络药理学技术来鉴定与疗效相关的有效成分和生物标志物。
利用高灵敏度 UPLC-MS 技术，从 YCHD 中鉴定出 69 种化合物，其中 41 种在血液中被吸收。此外，还鉴定出 34 种来自 DHJS 的尿液生物标志物。值得注意的是，我们利用中药组学技术对尿液生物标志物和吸收成分进行了相关性分析，确定了 9 个核心化合物作为 YCHD 功效的 Q-markers。最后，共发现 12 个潜在靶点。
本研究为阐明中药疗效和发现有效成分作为 Q-markers 提供了一种强有力的方法。
